Holen Sie sich die Stockscreener-App
0.2338
1.61%
0.0041
Schlusskurs vom Vortag:
$0.2297
Offen:
$0.229
24-Stunden-Volumen:
6.78M
Relative Volume:
1.12
Marktkapitalisierung:
$8.31M
Einnahmen:
$94,000
Nettoeinkommen (Verlust:
$-13.28M
KGV:
-0.032
EPS:
-7.2965
Netto-Cashflow:
$-11.67M
1W Leistung:
-0.51%
1M Leistung:
-18.22%
6M Leistung:
-67.78%
1J Leistung:
-90.91%
1-Tages-Spanne:
$0.2267
$0.237
1-Wochen-Bereich:
$0.2266
$0.2615
52-Wochen-Spanne:
$0.1901
$2.977
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.2341 | 8.16M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
522.11 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.76 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.30 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.67 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire
AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead - Stocktwits
Why Did AIM Stock Plummet 35% Today? - Stocktwits
AIM ImmunoTech Eliminates $1.22 Million Debt via Stock Exchange - Minichart
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
AIM ImmunoTech Extinguishes Debt Through Equity Exchanges - TipRanks
AIM ImmunoTech Significantly Expands Ampligen® Global - GlobeNewswire
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - The Manila Times
AIM ImmunoTech Secures European and U.K. Patent Protection for Ampligen in Long COVID Through 2041 - Quiver Quantitative
AIM ImmunoTech Extends IP Protection for Ampligen Through 2039 with Broad US Patent - Contract Pharma
AIM Looks 69.6% Undervalued on GF Value™ Despite Financial Distr - GuruFocus
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - The Manila Times
AIM ImmunoTech Secures U.S. Patent for Ampligen Combination with Pembrolizumab in Cancer Treatment - Quiver Quantitative
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod - GlobeNewswire
$AIM ImmunoTech (AIM.US)$ liquidity grabbs full - Moomoo
AIM Q2 2026 Earnings: Wider Than-Expected Loss as Clinical-Stage Costs PersistProfit Inflection Point - vinanet.vn
AIM ImmunoTech Inc. (AIM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
AIM ImmunoTech Inc. (AIM) Peer Comparison – Compare with Others - Value Research
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - The Manila Times
AIM ImmunoTech doses final patient in pancreatic cancer trial - stocktitan.net
AIM | AIM ImmunoTech Inc. FinancialsRevenue Breakdown - Quiver Quantitative
AIM ImmunoTech highlights pancreatic cancer program momentum - scanx.trade
AIM ImmunoTech (AIM) Stock Forecast & Analyst Ratings - Moomoo
AIM Maintained by Ascendiant Capital -- Price Target Lowered to $7.00 - GuruFocus
AIM (AIM) Earnings Snapshot: EPS Does Not Reach the Reported Estimate in the Latest Reading; After Earnings: The Share Price Adds 1.84% in the Latest SessionHigh Estimate Range - vinanet.vn
AIM ImmunoTech Q2 2026 Earnings: EPS Misses by Wide Margin as Shares Drop SharplyRevenue Guidance Range - dars.gov.et
AIM Q2 2026 Earnings: Wider-than-Expected Loss Prompts Investor CautionFinal Results - vinanet.vn
AIM ImmunoTech Inc (AIM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
$AIM ImmunoTech (AIM.US)$ - Moomoo
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR) - The Globe and Mail
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - The Manila Times
AIM's Ampligen-Treated Mouse Group Had 100% Ebola Survival - Stock Titan
AIM ImmunoTech CEO Urges Biodefense Military Integration - The Globe and Mail
Form 8K AIM ImmunoTech Inc For: 11 August By Investing.com - Investing.com Nigeria
Biodefense is force protection: Ready today, prepared for tomorrow - Breaking Defense
AIM ImmunoTech Releases Q2 2026 Financial Results - AlphaStreet
Form 8K AIM ImmunoTech Inc For: 10 August By Investing.com - Investing.com Australia
AIM ImmunoTech Q2 loss widens to $3.8M, EPS misses estimates - scanx.trade
AIM ImmunoTech Reports Completion of Phase 2 Ampligen Dosing in Metastatic Pancreatic Cancer Trial, Advances Phase 3 Planning - Quiver Quantitative
AIM ImmunoTech Reports Q2 2026: $9.9M Cash, $3.8M Net Loss - TradingView
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer - The Manila Times
AIM Completes Pancreatic Cancer Study Dosing; Phase 3 Planned - Stock Titan
AIM ImmunoTech (NYSE: AIM) returns to positive equity after new financings - Stock Titan
AIM ImmunoTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AIM ImmunoTech Inc (AIM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K AIM ImmunoTech Inc For: 6 August By Investing.com - Investing.com Nigeria
AIM ImmunoTech signs $1.5 million manufacturing agreement with Sterling Pharma - Investing.com
AIM ImmunoTech (AIM) inks $1.5M manufacturing pact for Ampligen - Stock Titan
AIM ImmunoTech (AIM) Climbs 7.98% as Biotech Micro-Cap Tests Key Resistance at $0.29PCR Spike - dars.gov.et
AIM ImmunoTechDuripanc Overall Survival En - Moomoo
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):